Horizon Therapeutics Public Limited (HZNP) Stock Analysis

What Horizon Therapeutics Public Limited does

Horizon Therapeutics Public Limited Company operates as a biotechnology enterprise, primarily concentrating on the identification, refinement, and commercialization of pharmaceutical products designed to address significant medical needs for individuals afflicted by rare, autoimmune, and severe inflammatory conditions. The company's operations are divided into two principal divisions: Orphan and Inflammation. Its extensive product lineup features twelve distinct medications, targeting therapeutic areas such as rare diseases, gout, ophthalmic conditions, and various forms of inflammation. Among its marketed offerings are TEPEZZA (an intravenous infusion), KRYSTEXXA (also administered intravenously), the oral liquid RAVICTI, PROCYSBI (available as oral delayed-release capsules and granules), the subcutaneous injectable ACTIMMUNE, BUPHENYL (oral tablets and powder), the inhaled solution QUINSAIR, and the intravenous injection UPLIZNA. Furthermore, the company's portfolio includes PENNSAID (a topical solution), DUEXIS (oral tablets), RAYOS (delayed-release oral tablets), and VIMOVO (delayed-release oral tablets). Horizon Therapeutics maintains strategic partnerships with several entities, including HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. Founded in 2005, the company, originally known as Horizon Pharma Public Limited Company, rebranded to its current name in May 2019. Its global headquarters are situated in Dublin, Ireland, complemented by additional offices located in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Key metrics

ETFs linked to HZNP

Broad-market and Healthcare sector ETFs an investor holding Horizon Therapeutics Public Limited is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how HZNP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Horizon Therapeutics Public Limited?

Horizon Therapeutics Public Limited trades under the ticker HZNP on NASDAQ.

Which exchange is HZNP listed on?

HZNP is listed on NASDAQ.

What sector does Horizon Therapeutics Public Limited operate in?

Horizon Therapeutics Public Limited is classified in the Healthcare sector (Drug Manufacturers - General industry).

How can PortView help analyze HZNP in a portfolio?

PortView shows HZNP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.